Hims Stock Surges on FDA Peptide Review

0:00Hems and her stock just got a major boost from the FDA announcing a meeting on July 23rd and 24th. Their Pharmacy Compounding Advisory Committee will review peptides like BPC157, KPV, TB500, and others for wider compounding. Access. Investors see this as a green light for Hems' peptide push, sending shares of over 7% in recent sessions. Earlier this year, in February 2025, Hems snapped up a California peptide facility to lock in their supply chain and dive into. Personalized meds for health, metabolism, cognition, recovery, and more. This move positions them perfectly ahead of the FDA review. Meanwhile, the timing lines up with Hems reshaping their weight loss game. Shifted to FDA-approved GLP-1 drugs from Novo Nordisk, limiting compounded somaglutide, which keeps their core business humming strong. On the number side, Hems crushed full-year 2025 with $2.35 billion in revenue of 59% and 6.

1:05117.8 million in the fourth quarter of 28%. We hit 2.51 million subscribers, posted 128.4 million in net income, and 318 million. Inadjusted EBITDA, guiding for 2.7 to 2.9 billion in revenue next year. With a growing platform, international expansion on deck, and this peptide review looming, the market's betting big on Hems opening new lanes in. Consumer health, just when they need it most. That wraps through our news today. Brought to you with AI. I'm Corey with The Story.